News coverage about Gemphire Therapeutics (NASDAQ:GEMP) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Gemphire Therapeutics earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.0840779644065 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Gemphire Therapeutics Inc. (GEMP) Rating Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- FY2017 EPS Estimates for Gemphire Therapeutics Inc. (GEMP) Lowered by Analyst (americanbankingnews.com)
- Gemphire Therapeutics Inc. (GEMP) Rating Increased to Buy at Zacks Investment Research (americanbankingnews.com)
- Gemphire Therapeutics Inc. (GEMP) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS (americanbankingnews.com)
- Gemphire Therapeutics’ (GEMP) Buy Rating Reiterated at HC Wainwright (americanbankingnews.com)
Gemphire Therapeutics (NASDAQ:GEMP) opened at $9.50 on Monday. The company has a quick ratio of 4.17, a current ratio of 4.17 and a debt-to-equity ratio of 1.00. Gemphire Therapeutics has a fifty-two week low of $7.20 and a fifty-two week high of $21.59.
Several analysts recently issued reports on GEMP shares. Zacks Investment Research downgraded shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. Canaccord Genuity reissued a “buy” rating on shares of Gemphire Therapeutics in a research report on Friday, October 13th. Jefferies Group LLC reduced their price target on shares of Gemphire Therapeutics from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, August 8th. HC Wainwright assumed coverage on shares of Gemphire Therapeutics in a report on Thursday, August 31st. They set a “buy” rating and a $21.00 price objective on the stock. Finally, Roth Capital assumed coverage on shares of Gemphire Therapeutics in a report on Thursday, October 19th. They set a “buy” rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $22.17.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://sportsperspectives.com/2017/11/20/gemphire-therapeutics-gemp-receiving-somewhat-positive-press-coverage-analysis-shows.html.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.